China Aoxing Pharmaceutical Company (中国奥星药业) has purchased the rights to a novel drug in Phase II trials that targets primary dysmenorrhea (PD), or menstrual pain. The drug, TJSL, is a capsule formulation of selected herbal medicines developed by Professor X. Tian, a well-known China gynecologist. Terms were not disclosed. With the initiative, China Aoxing will seek to extend its pain medication franchise into a new field. More details...

Stock Symbol: (OTCBB: CAXG)